Serious adverse events occurred in 64 ( 27 % ) of 240 patients receiving desmoteplase compared with 69 ( 29 % ) of 238 patients receiving placebo ; frequency of symptomatic intracranial haemorrhage ( six [ 3 % ] patients in the desmoteplase group vs five [ 2 % ] in the placebo group ) , symptomatic cerebral oedema ( five [ 2 % ] vs four [ 2 % ] ) , and major haemorrhage ( ten [ 4 % ] vs 15 [ 6 % ] ) was much the same between treatment groups .